REG - BioPharma Credit PLC - STATEMENT RE ALPHATEC PREPAYMENT

Biopharma CreditAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260506:nRSF2079Da&default-theme=true

RNS Number : 2079D  BioPharma Credit PLC  06 May 2026

6 May 2026

 

BIOPHARMA CREDIT PLC

 

(THE "COMPANY")

 

STATEMENT RE ALPHATEC PREPAYMENT

 

 

The Company notes the announcement released on 5 May 2026 by Alphatec
Holdings, Inc. ("ATEC") regarding the prepayment in full of its US$200 million
senior secured loan facility, of which the Company had an investment of US$35
million.  The Company announced its US$35 million investment in the US$200
million senior secured loan facility to ATEC on 31 October 2024. The Company
received a payment of US$37.1 million, comprised of US$35 million in return
principal and US$2.1 million of prepayment fees and accrued interest.  The
Company earned a 14.91 per cent. gross internal rate of return and 11.93 per
cent. net internal rate of return on its ATEC investment 1  (#_ftn1) .

 

 

 

Enquiries:

 

BioPharma Credit plc

via MUFG Corporate Governance Limited

Company Secretary

+44 (0) 333 300 1932

 

Burson Buchanan

Henry Wilson / Helen Tarbet / Jamie Hooper / Nick Croysdill

+44 (0)20 7466 5000

biopharmacredit@buchanan.uk.com (mailto:biopharmacredit@buchanan.uk.com)

 

Notes to Editors:

 

BioPharma Credit PLC is London's only specialist debt investor to the life
sciences industry and joined the LSE in March 2017. BioPharma Credit
PLC seeks to provide long-term shareholder returns, principally in the form
of sustainable income distributions from exposure to the life sciences
industry. BioPharma Credit PLC seeks to achieve this objective primarily
through investments in debt assets secured by royalties or other cash flows
derived from the sales of approved life sciences products.

 

 1  (#_ftnref1) Past performance is not an indication of future performance.
For more information as to how the Company calculates gross and net internal
rates of return as used herein, please refer to the disclaimer on page 1 of
the Company's investor presentation dated 20 April 2026, available on the
Company's website (https://bpcruk.com/company-presentation-april-2026/).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCAKABNPBKKCPK



            Copyright 2019 Regulatory News Service, all rights reserved